A response of systemic endocrine factors (i.e., parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23)) counterbalances renal phosphate retention and delays hyperphosphatemia at earlier CKD stages [5,6,7,8,9]. Here, FGF23 is linked to hyperphosphatemia.